83-2271-46　［受注停止］KRIBIOLISA Anti-Asparte （Novolog） ELISA 1 x 96 wells　KBI9003

特徴

• Description：Insulin aspart is a fast-acting insulin analog marketed by Novo Nordisk as NovoLog/NovoRapid.
• It is a manufactured form of human insulin; where a single amino acid has been exchanged.
• This change helps the fast-acting insulin analog be absorbed quickly into the bloodstream.
• As a result, it starts working in minutes, which allows one to take insulin and eat right away.
• Fast-acting insulin analogs are considered to act similarly to the way insulin is released in people without diabetes mellitus.
• It is a recombinant, biosynthetic, fast-acting insulin analogue.
• Compared to human insulin, it has a single amino acid substitution at position B28 where proline is replaced with aspartic acid.
• This substitution decreases its propensity to form hexamers and gives it a higher rate of absorption following subcutaneous administration compared to native insulin.
• Principle of the assay： The method employs the qualitative enzyme immunoassay technique.
• A commercially available Aspart is pre-coated onto microwells.
• Samples and Controls are pipetted into microwells and antibodies to human Aspart present in the sample and controls are bound by Aspart.
• In the second step, a HRP （horseradish peroxidase） conjugate is pipetted and incubated.
• Excess HRP conjugate will be removed by washing.
• Addition of TMB substrate will develop blue color and intensity of blue colour in wells are proportional to the concentration of anti- Aspart antibody present in Positive control or sample.
• Color development is then stopped by addition of stop solution.
• Absorbance is measured at 450 nm.